Chairman, MD and CEO retires; CFO promoted to Managing Director
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Prakash M. Patil retired early as Chairman, MD and CEO of Aarti Drugs, effective September 30, 2026. Adhish P. Patil, the previous CFO, has been promoted to Managing Director from October 1, 2026, after shareholder approval at the AGM on September 26. He relinquished the CFO role and the company will appoint a new CFO shortly. The transition appears orderly within the Patil family, with Prakash's term originally set to expire on May 31, 2027.
Family succession: Prakash M. Patil retires as Chairman, MD and CEO; Adhish Patil promoted to MD from CFO role. CEO and CFO posts to be filled.